CHIASMA, INC
DelistedCIK 1339469fmd_1VK1YB67MCSZ82FW5D6PQCZFRTManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Mar 31, 2021, 30 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | 1 |
| Cost of revenue | – | – | – | – | – | – | – | 0 |
| Gross profit | – | – | – | – | – | – | – | 1 |
| Research and development | 26 | 12 | 19 | 31 | 18 | 22 | 22 | 27 |
| Selling, general and administrative | 8 | 3 | 16 | 22 | – | 10 | 15 | 45 |
| Total operating expenses | 35 | 15 | 35 | 61 | 28 | 32 | 38 | 72 |
| Operating income | 39 | (2) | (35) | (61) | (28) | (32) | (38) | (71) |
| Interest expense | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Interest and investment income | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 1 |
| Other non-operating income (expense) | (1) | (0) | (0) | 1 | 1 | 1 | 2 | – |
| Income before taxes | 37 | (2) | (36) | (61) | (27) | (31) | (36) | (75) |
| Income tax expense | 1 | 0 | 0 | 0 | (1) | (0) | 0 | 0 |
| Net income from continuing operations | 36 | (2) | (36) | (61) | (27) | (31) | (36) | (75) |
| Net income | 36 | (2) | (36) | (61) | (27) | (31) | (36) | (75) |
| Net income to common shareholders | (5) | (3) | (36) | (61) | (27) | – | – | – |